These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37982298)

  • 1. Improving nanochemoimmunotherapy efficacy by boosting "eat-me" signaling and downregulating "don't-eat-me" signaling with
    Pang G; Wei S; Zhao J; Wang FJ
    J Mater Chem B; 2023 Dec; 11(48):11562-11577. PubMed ID: 37982298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle-Mediated CD47-SIRPα Blockade and Calreticulin Exposure for Improved Cancer Chemo-Immunotherapy.
    Luo JQ; Liu R; Chen FM; Zhang JY; Zheng SJ; Shao D; Du JZ
    ACS Nano; 2023 May; 17(10):8966-8979. PubMed ID: 37133900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
    Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
    J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An "eat me" combinatory nano-formulation for systemic immunotherapy of solid tumors.
    Abdel-Bar HM; Walters AA; Lim Y; Rouatbi N; Qin Y; Gheidari F; Han S; Osman R; Wang JT; Al-Jamal KT
    Theranostics; 2021; 11(18):8738-8754. PubMed ID: 34522209
    [No Abstract]   [Full Text] [Related]  

  • 5. SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the "don't eat me" signal and activating the "eat me" signal.
    Yu J; Li S; Chen D; Liu D; Guo H; Yang C; Zhang W; Zhang L; Zhao G; Tu X; Peng L; Liu S; Bai X; Song Y; Jiang Z; Zhang R; Tian W
    J Hematol Oncol; 2022 Nov; 15(1):167. PubMed ID: 36384978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα "don't eat me" immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation.
    Hendriks MAJM; Ploeg EM; Koopmans I; Britsch I; Ke X; Samplonius DF; Helfrich W
    Oncoimmunology; 2020 Sep; 9(1):1824323. PubMed ID: 33299654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment.
    Zhuang Z; Zhou J; Qiu M; Li J; Lin Z; Yi H; Liu X; Huang C; Tang B; Liu B; Li X
    Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
    Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
    Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 10. The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy?
    Beizavi Z; Gheibihayat SM; Moghadasian H; Zare H; Yeganeh BS; Askari H; Vakili S; Tajbakhsh A; Savardashtaki A
    Mol Biol Rep; 2021 Jul; 48(7):5707-5722. PubMed ID: 34275112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 Vpu Promotes Phagocytosis of Infected CD4
    Cong L; Sugden SM; Leclair P; Lim CJ; Pham TNQ; Cohen ÉA
    mBio; 2021 Aug; 12(4):e0192021. PubMed ID: 34425695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis.
    Wang Y; Zhao C; Liu Y; Wang C; Jiang H; Hu Y; Wu J
    Mol Pharm; 2022 May; 19(5):1273-1293. PubMed ID: 35436123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of CD47 and signal-regulatory protein-α constituting the "don't eat me signal" is a prognostic factor in diffuse large B-cell lymphoma.
    Kazama R; Miyoshi H; Takeuchi M; Miyawaki K; Nakashima K; Yoshida N; Kawamoto K; Yanagida E; Yamada K; Umeno T; Suzuki T; Kato K; Takizawa J; Seto M; Akashi K; Ohshima K
    Cancer Sci; 2020 Jul; 111(7):2608-2619. PubMed ID: 32342603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.
    Cendrowicz E; Jacob L; Greenwald S; Tamir A; Pecker I; Tabakman R; Ghantous L; Tamir L; Kahn R; Avichzer J; Aronin A; Amsili S; Zorde-Khvalevsky E; Gozlan Y; Vlaming M; Huls G; van Meerten T; Dranitzki ME; Foley-Comer A; Pereg Y; Peled A; Chajut A; Bremer E
    J Exp Clin Cancer Res; 2022 Mar; 41(1):97. PubMed ID: 35287686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoscale imaging of CD47 informs how plasma membrane modifications shape apoptotic cell recognition.
    Dufour S; Tacnet-Delorme P; Kleman JP; Glushonkov O; Thielens N; Bourgeois D; Frachet P
    Commun Biol; 2023 Feb; 6(1):207. PubMed ID: 36813842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Fc Receptor-Mediated Effects and the "Don't Eat Me" Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer.
    Tian L; Xu B; Teng KY; Song M; Zhu Z; Chen Y; Wang J; Zhang J; Feng M; Kaur B; Rodriguez L; Caligiuri MA; Yu J
    Clin Cancer Res; 2022 Jan; 28(1):201-214. PubMed ID: 34645647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell 'don't eat me' signals off and 'eat me' signals on.
    Mohanty S; Aghighi M; Yerneni K; Theruvath JL; Daldrup-Link HE
    Mol Oncol; 2019 Oct; 13(10):2049-2061. PubMed ID: 31376208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD47/SIRPα axis: bridging innate and adaptive immunity.
    van Duijn A; Van der Burg SH; Scheeren FA
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35831032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
    Wang X; Wang Y; Hu J; Xu H
    Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glioblastoma Phagocytic Cell Death: Balancing the Opportunities for Therapeutic Manipulation.
    Du R; Tripathi S; Najem H; Brat DJ; Lukas RV; Zhang P; Heimberger AB
    Cells; 2024 May; 13(10):. PubMed ID: 38786045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.